Fmr LLC Vaxart, Inc. Transaction History

Fmr LLC

$1.68 Trillion
Q2 2025

A detailed history of Fmr LLC transactions in Vaxart, Inc. stock. As of the latest transaction made, Fmr LLC holds 200 shares of VXRT stock, worth $70. This represents 0.0% of its overall portfolio holdings.

Number of Shares

200

Holding current value

$70

% of portfolio

0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.31 - $0.7 $62 - $140	200 New	200 $0
Q4 2024 Feb 13, 2025	SELL	$0.54 - $0.86 $1,308 - $2,084	-2,424 Reduced 92.91%	185 $0
Q3 2024 Nov 13, 2024	SELL	$0.58 - $0.99 $484 - $826	-835 Reduced 24.25%	2,609 $2,000
Q2 2024 Aug 13, 2024	SELL	$0.53 - $1.3 $8,021 - $19,675	-15,135 Reduced 81.46%	3,444 $2,000
Q1 2024 May 13, 2024	SELL	$0.56 - $1.41 $14,042 - $35,355	-25,075 Reduced 57.44%	18,579 $24,000
Q4 2023 Feb 13, 2024	SELL	$0.57 - $0.85 $10,122 - $15,094	-17,758 Reduced 28.92%	43,654 $24,000
Q3 2023 Nov 13, 2023	BUY	$0.69 - $0.85 $27,181 - $33,484	39,393 Added 178.9%	61,412 $46,000
Q2 2023 Aug 11, 2023	BUY	$0.6 - $1.41 $4,553 - $10,700	7,589 Added 52.59%	22,019 $16,000
Q1 2023 May 11, 2023	BUY	$0.71 - $1.25 $4,654 - $8,193	6,555 Added 83.24%	14,430 $10,000
Q4 2022 Feb 13, 2023	BUY	$0.75 - $2.24 $1,424 - $4,253	1,899 Added 31.78%	7,875 $7,000
Q3 2022 Nov 10, 2022	BUY	$2.09 - $4.5 $7,394 - $15,921	3,538 Added 145.12%	5,976 $13,000
Q2 2022 Aug 12, 2022	BUY	$2.7 - $5.28 $3,115 - $6,093	1,154 Added 89.88%	2,438 $9,000
Q1 2022 May 13, 2022	BUY	$4.29 - $6.64 $5,508 - $8,525	1,284 New	1,284 $6,000
Q3 2021 Nov 15, 2021	SELL	$6.67 - $9.8 $135,594 - $199,224	-20,329 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$5.06 - $10.78 $102,864 - $219,146	20,329 New	20,329 $152,000

Others Institutions Holding VXRT

# of Institutions

104

Shares Held

23.1M

Call Options Held

66.1K

Put Options Held

View Full List

About Vaxart, Inc.

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $44.3M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

More about VXRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account